DTIL Volume dana dhuwit perusahaan Precision BioSciences

Logo grafis Precision BioSciences Inc. (DTIL)

Precision BioSciences owns the unique ARCUS system, which provides exceptional pricing power due to the precision of its genome editing. These advantages translate into future licensing and therapy revenues, as clearly demonstrated by the cash balance. The value of 0.08 characterizes this liquidity assessment parameter. The process is being accelerated by the implementation of robotic stations for automated molecular screening.

DTIL - Aset likuid perusahaan precisionbiosciences.com ing rentang 04.07.2022 - 21.11.2026

Precision BioSciences, Inc. (DTIL) - rincian metrik lan laporan keuangan

- nilai saham lan prakiraan konsensus rega:
Analisis fundamental perusahaan:precisionbiosciences.com
Produk mawa merek precisionbiosciences.com

Given the exceptional value of the ARCUS platform and the inelastic demand for its technologies, the free cash flow of Precision BioSciences (DTIL) serves as an indicator of financial autonomy during the development of intellectual property. This metric aggregates cash and cash equivalents, allowing for an assessment of the balance between protection against market volatility and the efficiency of reinvesting capital into business expansion.

Pesaing Precision BioSciences (DTIL)

Volume dana dhuwit perusahaan TEM|QGEN - Cadangan dhuwit perusahaan|ionispharma.com - Dhuwit awis perusahaan|Sisa dhuwit perusahaan RGEN|Avidity Corp - Volume dana dhuwit perusahaan|CRISPR Therapeutics Corp - Gunggung dana dhuwit perusahaan|GeneDx Holdings (WGS) - Dana dhuwit perusahaan|Ultragenyx Pharmaceutical (RARE) - Volume dana dhuwit perusahaan|Dhuwit awis perusahaan BEAM|Sarepta (SRPT) - Aset likuid perusahaan|Dana dhuwit perusahaan Twist Bioscience Corp (TWST)|10x - Dhuwit awis lan setara dhuwit awis perusahaan|Volume dana dhuwit perusahaan NTLA (intelliatx.com)|Gunggung dana dhuwit perusahaan STOK (stoketherapeutics.com)|BioLife Solutions Inc - Volume dana dhuwit perusahaan|WVE (Wave Life Sciences Ltd) - Dhuwit awis lan setara dhuwit awis perusahaan|Maze Therapeutics Corp (MAZE) - Dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan SION|PRME (Prime Medicine Inc) - Volume dana dhuwit perusahaan|Taysha Gene Therapies (TSHA) - Aset likuid perusahaan|Dhuwit awis perusahaan QURE (uniqure.com)|Gunggung dana dhuwit perusahaan MGTX|Volume dana dhuwit perusahaan RGNX (regenxbio.com)|SLDB: Dhuwit awis lan setara dhuwit awis perusahaan|ocugen.com - Volume dana dhuwit perusahaan|PACB - Volume dana dhuwit perusahaan|BNTC: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan DSGN|Dana dhuwit perusahaan Rocket Pharmaceuticals|Dhuwit awis perusahaan 4DMT (FDMT)|Volume dana dhuwit perusahaan LXEO|Aset likuid perusahaan Korro Bio Inc.|Volume dana dhuwit perusahaan EDIT (Editas Medicine Inc)|SLN: Dhuwit awis lan setara dhuwit awis perusahaan|PRQR - Dana dhuwit perusahaan|Aset likuid perusahaan codexis.com CDXS|SGMO: Volume dana dhuwit perusahaan|Nautilus Biotechnology (NAUT) - Volume dana dhuwit perusahaan|Dana dhuwit perusahaan Metagenomi, Inc|generationbio.com (GBIO) - Aset likuid perusahaan|Dana dhuwit perusahaan Boundless Bio Inc (BOLD)|Volume dana dhuwit perusahaan Exicure Inc. (XCUR)|Dana dhuwit perusahaan imunon.com IMNN|Volume dana dhuwit perusahaan Phio Pharmaceuticals PHIO|Mustang Bio Inc - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan transcodetherapeutics.com|BNGO: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan APDN|BLUE (bluebirdbio.com) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan ImmunoPrecise Antibodies IPA|Dhuwit awis perusahaan OMGA (omegatherapeutics.com)|Volume dana dhuwit perusahaan Singular Genomics Systems, Inc. (OMIC)|Volume dana dhuwit perusahaan RGLS (Regulus Therapeutics, Inc.)|Volume dana dhuwit perusahaan Syros SYRS|Telesis Bio, Inc. - Volume dana dhuwit perusahaan|TRACON Pharmaceuticals (TCON) - Dhuwit awis perusahaan|UBX: Volume dana dhuwit perusahaan